Score Overview
Explore the 2021 public Archive ranking โ
Where Anebulo Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ANEB does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-12 | $ 0.32 | โ |
1 Year2025-10-13 | $ 2.32 | -86.42% |
5 Years2021-10-13 | $ 7.00 | -95.50% |
All Time2021-05-07 | $ 7.10 | -95.56% |
| Period | Last Price2026-10-12 | 1 Year2025-10-13 | 5 Years2021-10-13 | All Time2021-05-07 |
|---|---|---|---|---|
| Price | $ 0.32 | $ 2.32 | $ 7.00 | $ 7.10 |
| Return | โ | -86.42% | -95.50% | -95.56% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 7M | $ 9M |
| 2025 | $ 0.00 | -$ 8M | $ 11M |
| 2024 | $ 0.00 | -$ 8M | $ 3M |
| 2023 | $ 0.00 | -$ 11M | $ 11M |
| 2022 | $ 0.00 | -$ 6M | $ 14M |
| IPO2021 | $ 0.00 | -$ 30M | $ 19M |

Anebulo Pharmaceuticals Inc fundamental performance
Across Anebulo Pharmaceuticals Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 30M to -$ 8M. Revenue increased in 0% of the years measured; net income in 60%.
Membership
Explore ANEB with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,125 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio




